CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Sysmex joins Lab 2.0
October 2019—Sysmex America has joined the Clinical Lab 2.0 movement to support collaboration around value-based health care. The company said it is providing a grant focused on a multi-institutional demonstration project to develop actionable clinical strategies for anemia early detection, intervention, and prevention.
Clinical Lab 2.0 is a Project Santa Fe Foundation initiative established to help develop the evidence base for the valuation of clinical laboratory services. It is a call for laboratory leadership in managing population health and enabling value-based care to evolve. Sysmex is the first corporate sponsor.
“The Clinical Lab 2.0 movement, with its critical measurable and actionable attributes, promotes the clinical and business model of the future for clinical laboratories,” Khosrow Shotorbani, president and executive director of Project Santa Fe Foundation, said in a statement.
The third annual Clinical Lab 2.0 Workshop will take place Nov. 3–5 in Chicago (www.cl2lab.org/clinical-lab-2-0-3rd-annual-workshop-registration-2-2/).
AMP recommends pharmacogenomic testing best practices
The Association for Molecular Pathology published on Sept. 4 a new position statement for pharmacogenomic testing. The statement is based on a recent assessment of the market landscape, the AMP says, and includes a list of criteria for laboratories to follow to ensure responsible use of pharmacogenomic tests, preserve broad access, and improve patient care.